Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10830392 | 0.83 | TDP1 (0.39) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7575623 | 0.83 | CYP3A4 (0.36) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7575621 | 0.83 | CYP3A4 (0.38) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL8057311 | 0.83 | TSHR (0.40) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7577226 | 0.81 | TSHR (0.43) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL5928210 | 0.80 | CYP3A4 (0.39) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7575374 | 0.78 | CYP3A4 (0.38) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7583905 | 0.78 | CYP3A4 (0.35) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL7582924 | 0.78 | CYP3A4 (0.35) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL476238 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788363-B1 | HYDROLYSABLE SILANES | DOW CORNING (US) | 2018-04-25 | — | — | EP | claimed |
| US-9321792-B2 | Hydrolysable silanes | DOW CORNING CORPORATION (US) | 2016-04-26 | — | — | US | claimed |
| US-20140364627-A1 | Hydrolysable Silanes | DOW SILICONES CORPORATION | 2014-12-11 | — | — | US | claimed |
| EP-2788363-A1 | HYDROLYSABLE SILANES | Dow Corning Corporation (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083743-A1 | HYDROLYSABLE SILANES | DOW CORNING CORPORATION (US) | 2013-06-13 | — | — | WO | claimed |
| EP-2788363-B1 | HYDROLYSABLE SILANES | DOW CORNING (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9321792-B2 | Hydrolysable silanes | DOW CORNING CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140371392-A1 | Polymeric Materials Modified By Silanes | DOW CORNING EUROPE S.A. (BE) | 2014-12-18 | — | — | US | disclosed |
| US-20140364627-A1 | Hydrolysable Silanes | DOW SILICONES CORPORATION | 2014-12-11 | — | — | US | disclosed |
| US-20140329976-A1 | Treatment Of Filler With Silane | DOW CORNING EUROPE S.A. (BE) | 2014-11-06 | — | — | US | disclosed |
| EP-2788363-A1 | HYDROLYSABLE SILANES | Dow Corning Corporation (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2788387-A2 | POLYMERIC MATERIALS MODIFIED BY SILANES | Dow Corning Corporation (US) | 2014-10-15 | — | — | EP | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0030474-B1 | PROCESS FOR THE PRODUCTION OF DL-SERINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1983-01-19 | — | — | EP | disclosed |
| US-4304933-A | HEATING AZIRIDINE-2-CARBOXYLIC ACID ON ION EXCHANGE RESIN | MITSUI TOATSU CHEMICALS, INC. (JP) | 1981-12-08 | — | — | US | disclosed |
| EP-0030474-A1 | Process for the production of DL-serines | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1981-06-17 | — | — | EP | disclosed |
| US-4198509-A | Mercaptoacylpiperazine carboxylic acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329976-A1 | Treatment Of Filler With Silane | CD44, ASAH2, COL2A1 | TSHR 4040/4885ALDH1A1 1399/4885CYP3A4 4528/4885 |
| US-20140364627-A1 | Hydrolysable Silanes | ESD, JMJD6, KDM5A | TSHR 4559/4885ALDH1A1 376/4885CYP3A4 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.